University of Ioannina
Κλινικά και εργαστηριακά ευρήματα πομφολυγώδους πεμφιγοειδούς σε ασθενείς με σακχαρώδη διαβήτη τύπου ΙΙ υπό αγωγή με γλιπτίνες
Abstract
dc:descriptionBullous pemhigoid (BP) is the most common acquired blistering disease affecting mainly the elderly. Its pathogenesis is mediated by autoimmune mechanisms targeting epitopes expressed on the hemidesmosomes of the basal membrane and the inflammatory process that follows results in the dermo-epidermal detachment and the formation of subepidermal blisters. Ιt may be associated with other underlying comorbidities (e.g. autoimmune disorders, malignancies) and triggering oraggravating factors such as trauma and certain medicine. Recently, accumulated datasuggests among culprit drugs a major role of Dipeptidyl Peptidase-4 inhibitors (DPP4i) as a disease trigger. DPP4is -or else gliptins- are hypoglycemic agents prescribed to Diabetes mellitus type 2 patients (DMT2). The aforementioned patientgroup consists a particularly vulnerable group of patients, considering the possible deregulation of glucose levels following gliptin discontinuation along with the additional burden of the administration of systemic glucocorticosteroids which still remain the cornerstone of the treatment of moderate-to-severe BP cases, according to guidelines.Τhe present study demonstrates the significant contribution of the over timeincreasing use of gliptins in the observed increasing prevalence of DMT2 among newly diagnosed cases of BP throughout the years 2010-2016, which also resulted in a parallel upward trend in the total of new cases of BP admitted in the Dermatology Department of University Hospital of Ioannina during the same time period. In addition, it comprises comparisons concerning epidemiologic, clinical and laboratory findings among patient groups with or without preceded use of DPP4i. Statistical evaluation of the relevant data did not reveal significant differences in thedemographic parameters (age, sex), the diagnostic laboratory tests’ results (biopsy,direct/indirect immunofluorsce, ELISA), the clinical findings suggestive of BP diagnosis and the treatment regimens in the sense of the therapeutic demandings for achieving and maintaining disease control. Regarding any comorbidities, the only statistically significant association was that of gliptin use and metabolic diseases (dyslipidemia, hyperuricemia) which are strongly correlated with Diabetes Mellitus (chi square test=10.546, p=0.001).Comparative analysis of comorbidities and concomitant medication among patient groups with preceded use of gliptins with or without BP revealed a statisticallysignificant higher frequency of statin coadministration among patients not affected byBP despite previous treatment with a DPP4i. This observation, combined with data from the literature, supports a definite immunoregulatory effect of statins, potentially protective against BP among patients using gliptins.Upon confirming that previous use of DPP4i did not differentiate treatment demands for BP control, we evaluated the therapeutic efficacy of the combination of methylprednisolone (MP) and methotrexate (MTX) for this disease. Employing primary (percentage of patients achieving disease control, percentage of patients with a relapse) and secondary end points (time to disease control, time till first relapse, total methylprednisolone dose and methylprednisolone tapering rate till disease control), we proved both the feasibility and the efficacy of the coadministration of MP and MTX as a starting combination modality for all patients with adequate compliance to this treatment. In addition, follow up of specific parameters at the end of the 3rd month after initiating treatment (daily dose of methylprednisolone and weekly dose of methotrexate at the end of the first trimester as well as the total 3-month methylprednisolone dose) confirmed the significant ‘costicosteroid’ sparingeffect of this therapeutic intervention.Furthermore, considering the limitations of the present retrospective study, in an attempt to evaluate longterm safety and efficacy of the treatment by analysing the disease relapses, it is remarkable that more than 50% of the patients (73,6±10,2%) remained without a relapse for a period of 4 years after diagnosis. (Kaplan-Meier method).The safety profile of the treatment protocol was also satisfactory. Serious adverse events that occurred during treatment and that could be attributed exclusively to the use of systemic corticosteroids included 2 deaths (3.77% of the population group) and 4 cases (7.55%) of forced regimen modification.Given the retrospective character of the study, a basic limitation was the lack of acontrol arm, i.e. of patients treated with glucocorticosteroid monotherapy - the first line treatment according to guideline proposals. For this reason, we evaluated the efficacy of the present modality by comparing the measured end-point treatment parameters of this cohort (time to disease control, daily MP dose at 3 months and cumulative 3 month MP dose) with the corresponding endpoints anticipated by calculating different treatment scenarios of glycocorticosteroid monotherapy management (fast, moderate, slow tapering rates)based on expert-proposed treatment guidelines. The results confirmed an overall superior efficacy of the applied combined treatment regarding the aforementioned parameters, in addition to the MP sparing effect.Finally, comparative analysis of treatment endpoints for the different MP-MTX combinations provides clues in favour of a therapeutic superiority of the combination 48mg MP+7.5mg MTX as initial treatment regimen. Overall, the present study contributes to the better understanding of the nosological aspects of the gliptin intake related BP while it also suggests a safe and probably more efficient treatment modality for this disease that could reduce the burden of administered glucocorticosteroids. The latter, if confirmed in larger trials, may prove an important finding of particular interest for the management of the vulnerable group of elderly patients with diabetes mellitus and bullous pemphigoid.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gravani, Agoritsa
- Γραβάνη, Αγορίτσα
Subjects
dc:subject × 8Rights
dc:rights- Statement dc:rights
-
- BY_NC_4_0
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49522